AF
TBPH icon

Amalgamated Financial’s Theravance Biopharma TBPH Stock Holding History

Amalgamated Financial’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$91K Buy
+9,556
New +$93.6K ﹤0.01% 2183

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Amalgamated Financial's TBPH Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Theravance Biopharma (TBPH) in Q1 2022: 9,556 shares worth $91K. The stake represents ﹤0.01% of the portfolio and ranks #2183 among its holdings.

121 funds tracked by Wall St. Rank hold TBPH as of Q1 2022.

  • Amalgamated Financial held 9,556 shares of Theravance Biopharma worth $91K as of Q1 2022.
  • Theravance Biopharma was a new Amalgamated Financial position in Q1 2022.
  • Theravance Biopharma made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2183 holding.
  • 121 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.